February 10, 2011
New Report by Arrowhead Publishers Assesses Future Market Impact of Therapeutic Cancer Vaccines
In 2010, the therapeutic cancer vaccine market witnessed several key milestones. Dendreon’s Provenge (sipuleucel-T) became the first product to reach the market; gaining long-awaited FDA approval for metastatic hormone-refractory prostate cancer. The Cancer Research Institute (CRI) and the Cancer Immunotherapy Consortium (CIC) also proposed much needed criteria to standardize vaccine clinical trials.
Although the major milestones attained in the clinical development of therapeutic cancer vaccines has brought hope and guidance for investors, the market is in its commercial infancy. According to Arrowhead Publishers’ new publication, The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact, numerous challenges must be overcome to create optimal vaccines on an economical scale. Stakeholders can learn from Provenge’s developmental pathway to maximize success in this potentially lucrative market.
With over 1.3 million people having been diagnosed with colorectal cancer, breast cancer, lung cancer, prostate cancer, pancreatic cancer or melanoma across the seven major markets in 2010, coupled with unsatisfactory survival rates; vaccines could hold the ability to transform the management of cancer.
- Traditional cancer clinical trial endpoints are not always applicable in the assessment of cancer vaccines. Lengthy trials allowing full data maturation of measuring immune response is limiting market entry. R&D must establish an effective and consistent way to assess vaccines.
- Arrowhead has identified almost 400 clinical trials investigating therapeutic oncology vaccines. Whole-cell vaccines are the most popular design in late-stage development. Arrowhead anticipates a wave of products to reach the market over the coming decade.
- The market is set to become highly competitive, especially within the lung cancer and melanoma sectors. By 2020 the market could be worth $8 billion. Top revenue earning candidates include GSK’s MAGE-ASCI-A3, Merck/Oncothyreon’s Stimuvax (BLP25), NovaRX’s Lucanix and Lorus Therapeutics/Zor Pharma’s Virulizin.
For more information about this report, CLICK HERE
To order this report, CLICK HERE